Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
87.75 GBX | +0.29% | +5.09% | +13.96% |
May. 23 | Celadon ships to US; Oxford BioDynamics-Goodbody pact | AN |
Apr. 25 | Anglo American share spike before bid raises questions about leaks | RE |
Valuation
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 213.1 | 198.5 | 82.22 | 90.99 | 96.13 | 52.02 |
Enterprise Value (EV) 1 | -37.04 | -43.82 | -12.77 | -36.1 | -24.78 | -30.1 |
P/E ratio | 4.85 x | 21.7 x | -0.64 x | 2.72 x | 11 x | -9.33 x |
Yield | 2.28% | 2.42% | 2.79% | 4.61% | 17.3% | 56% |
Capitalization / Revenue | 3.46 x | 12 x | -0.64 x | 2.29 x | 14.2 x | -24.3 x |
EV / Revenue | -0.6 x | -2.65 x | 0.1 x | -0.91 x | -3.67 x | 14.1 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -1.2 x | 15.2 x | 0.14 x | -1.21 x | 16.7 x | -16.7 x |
FCF Yield | -83.2% | 6.56% | 692% | -82.4% | 5.99% | -5.99% |
Price to Book | 0.9 x | 0.83 x | 0.84 x | 0.74 x | 0.8 x | 0.67 x |
Nbr of stocks (in thousands) | 97,326 | 95,882 | 91,862 | 83,862 | 83,231 | 83,231 |
Reference price 2 | 2.190 | 2.070 | 0.8950 | 1.085 | 1.155 | 0.6250 |
Announcement Date | 9/7/18 | 9/13/19 | 9/21/20 | 9/28/21 | 11/30/22 | 10/24/23 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 61.56 | 16.51 | -128.1 | 39.76 | 6.756 | -2.138 |
EBITDA | - | - | - | - | - | - |
EBIT 1 | 44.84 | 9.126 | -131.8 | 37.06 | 3.952 | -3.893 |
Operating Margin | 72.84% | 55.27% | 102.92% | 93.21% | 58.51% | 182.11% |
Earnings before Tax (EBT) 1 | 44.19 | 9.225 | -131.3 | 34.57 | 8.781 | -5.576 |
Net income 1 | 44.19 | 9.225 | -131.3 | 34.57 | 8.781 | -5.576 |
Net margin | 71.79% | 55.87% | 102.5% | 86.94% | 129.99% | 260.81% |
EPS 2 | 0.4515 | 0.0954 | -1.400 | 0.3990 | 0.1053 | -0.0670 |
Free Cash Flow 1 | 30.82 | -2.875 | -88.33 | 29.73 | -1.485 | 1.801 |
FCF margin | 50.06% | -17.41% | 68.96% | 74.78% | -21.98% | -84.26% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | 69.74% | - | - | 86.02% | - | - |
Dividend per Share 2 | 0.0500 | 0.0500 | 0.0250 | 0.0500 | 0.2000 | 0.3500 |
Announcement Date | 9/7/18 | 9/13/19 | 9/21/20 | 9/28/21 | 11/30/22 | 10/24/23 |
Balance Sheet Analysis
Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 250 | 242 | 95 | 127 | 121 | 82.1 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | 30.8 | -2.88 | -88.3 | 29.7 | -1.48 | 1.8 |
ROE (net income / shareholders' equity) | 20.1% | 3.87% | -78.1% | 31.4% | 7.21% | -5.62% |
ROA (Net income/ Total Assets) | 12.2% | 2.31% | -48.2% | 20.6% | 1.99% | -2.4% |
Assets 1 | 363.2 | 399.9 | 272.4 | 168 | 441.7 | 232.8 |
Book Value Per Share 2 | 2.450 | 2.490 | 1.060 | 1.470 | 1.450 | 0.9300 |
Cash Flow per Share 2 | 0.0100 | 0.0100 | 0.0600 | 0.0700 | 0 | 0.1500 |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 9/7/18 | 9/13/19 | 9/21/20 | 9/28/21 | 11/30/22 | 10/24/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+13.96% | 82.27M | |
+7.69% | 13.26B | |
+11.85% | 9.55B | |
+2.65% | 5.74B | |
+7.30% | 5.27B | |
-0.71% | 5.11B | |
+26.36% | 4.99B | |
+20.18% | 4.59B | |
+5.29% | 3.97B | |
+1.45% | 3.98B |
- Stock Market
- Equities
- CRS Stock
- Financials Crystal Amber Fund Limited